Photo from wikipedia
Nivolumab demonstrated durable responses and safety in patients with hepatocellular carcinoma (HCC) with Child‐Pugh class A cirrhosis in the CheckMate 040 trial, with rates of hepatotoxicity that were similar to… Click to show full abstract
Nivolumab demonstrated durable responses and safety in patients with hepatocellular carcinoma (HCC) with Child‐Pugh class A cirrhosis in the CheckMate 040 trial, with rates of hepatotoxicity that were similar to those of non‐HCC populations. To the authors' knowledge, the safety and efficacy of nivolumab has not been established in patients with Child‐Pugh class B (CPB) cirrhosis, a population with limited therapeutic options and a poor prognosis.
Keywords:
hepatocellular carcinoma;
cirrhosis;
safety;
child pugh;
pugh class
Journal Title: Cancer
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!